Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) has achieved
impressive clinical results with durable complete responses in patients with metastatic
melanoma. The TILs are isolated from patients own tumor tissue followed by in vitro expansion
and activation for around 4-6 weeks. Before TIL infusion the patients receive 1 week of
preconditioning chemotherapy with cyclophosphamide and fludarabine. After TIL infusion
Interleukin-2 is administered to support T cell activation and proliferation in vivo.
Recent studies suggest, that TIL therapy works in other cancers than Metastatic Melanoma,
including Renal Cell Carcinoma. In this study TIL therapy is administered to patients with
metastatic Renal Cell Carcinoma.